Navigation Links
FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Group's Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma
Date:3/31/2011

SAN DIEGO, March 31, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that the U.S. Food & Drug Administration (FDA) has approved the company's Special Protocol Assessment (SPA) for a Phase 3 clinical trial of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced hepatocellular carcinoma (HCC). The randomized, placebo-controlled, global trial will enroll approximately 600 patients who have failed prior systemic chemotherapy. The primary endpoint of the study is overall survival.

Ghassan Abou-Alfa, M.D., of Memorial Sloan-Kettering Cancer Center in New York, is the principal investigator of the study.  

"ADI-PEG 20 has demonstrated medical benefit in prior studies in multiple indications with a remarkable safety profile," said Dr. Abou-Alfa. "I am delighted to lead this study to explore ADI-PEG 20 as a viable option for patients with advanced liver malignancies."

SPA is a mechanism that allows the FDA and drug developers to reach an agreement prior to study initiation about the design and size of a Phase 3 trial. It will form the primary basis of an efficacy claim in a marketing application.

"The SPA agreement with the FDA is a key step in our plans for the clinical development of ADI-PEG 20," said John Bomalaski, M.D., executive vice president, medical affairs, of Polaris. "We are pleased to move ADI-PEG 20 into a pivotal Phase 3 trial and to be working with such well-established hepatocellular carcinoma experts."

Leo Chen, M.D., the lead investigator of the Phase 2 HCC study in Taiwan, stated, "Our Phase 2 study demonstrated that ADI-PEG 20 was effective and well-tolerated in patients with advanced liver cancer, and we look forward to the opportunity to further assess the efficacy and safety of this drug in a large randomized Phase 3 study."

The lead investigator in China, Shukui Qin, M.D., president of the Chinese Society of Clinical Oncology and chair of the Chinese Liver Cancer Stu
'/>"/>

SOURCE Polaris Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Hyperopia Application for the MEL 80 Excimer Laser from Carl Zeiss Meditec
2. FDA Approves New Treatment for a Type of Late-Stage Skin Cancer
3. FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age
4. FDA Approves Gadavist for Central Nervous System Scans
5. U.S. FDA Approves Bayers Gadavist™ (Gadobutrol) Injection for MRI of the Central Nervous System
6. FDA Approves Device to Maintain Blood Flow During Artery Bypass Brain Surgery
7. FDA Approves BENLYSTA® for Lupus in Breakthrough for Millions of Sufferers
8. FDA Approves Revised Alphanate® Labeling to Include Reduced Infectivity of an Experimental Model Agent for vCJD
9. UPDATE: FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
10. FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
11. FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Md., June 01, 2007 /PRNewswire-FirstCall/ --,EntreMed, Inc. ... the treatment of cancer and inflammatory diseases,announced ... Aurora,kinase - angiogenesis inhibitor, ENMD-981693. The data ... EntreMed,scientists at the 2nd Protein Kinases in ...
... Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. ... ongoing clinical,studies of SNS-595 and SNS-032 at the ... held June 7-10, 2007 in Vienna,Austria. , Presentations ... 1 clinical trial of SNS-595 in acute leukemias, ...
Cached Medicine Technology:EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 2EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 3Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3
(Date:7/11/2014)... 11, 2014 Shoulder instability is a ... return to play has not been regularly determined following ... Society for Sports Medicine’s ( AOSSM ) Annual Meeting ... approximately 90 percent no matter what the stabilization procedure ... rate of return to play following shoulder stabilization surgery. ...
(Date:7/11/2014)... occur more than 200,000 times a year, but the ... may determine how long you stay in the game, ... Meeting of the American Orthopaedic Society of Sports Medicine ... in a young athletic population, allografts (tissue harvested from ... harvested from the patient)," said Craig R. Bottoni, MD, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Woodland Hills ... founder of the Anacapa Dental Art Institute in Woodland Hills ... Biocare World Symposium in Marina Del Rey, Calif. , ... master class on the permanent teeth in one day dental ... teeth in one day was developed 15 years ago, Dr. ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The World Cup ... according to recent reports , many star soccer players left ... in the media to American football when it comes to ... risk is always there. While none of the soccer superstars ... possibility remains. Beverly Hills spine surgeon Dr. Gravori reveals some ...
(Date:7/11/2014)... 2014 On Tuesday, July 9, Eric ... VA office joined CBS affiliate WUSA’s Andrea Roane ... the audience about the number of ways Shady Grove ... motherhood possible for women after they undergo cancer ... patients in the developing field known as oncofertility which ...
Breaking Medicine News(10 mins):Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2Health News:ACL reconstructions may last longer with autografts 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 3Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 4Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 5Health News:As World Cup Comes to an End, Injuries are Star of the Show 2Health News:As World Cup Comes to an End, Injuries are Star of the Show 3Health News:Baby After Cancer Is a Reality as Shady Grove Fertility Provides Successful Treatment for Cancer Survivors 2Health News:Baby After Cancer Is a Reality as Shady Grove Fertility Provides Successful Treatment for Cancer Survivors 3Health News:Baby After Cancer Is a Reality as Shady Grove Fertility Provides Successful Treatment for Cancer Survivors 4
... The University of Houston (UH) will soon open its doors ... a new joint venture between the UH Graduate College of ... Cancer Center Division of Cancer Prevention and Population Sciences. CHEER ... the newly opened center at UH GCSW. CHEER ...
... blood vitamin D levels, there,s uncertainty about where the ... threshold amount has become controversial as several scientific societies ... University of Washington researchers conducted an observational study. They ... circulating in the blood to lower the risk of ...
... , TUESDAY, May 1 (HealthDay News) -- Children with ... hospitalized than children without arthritis, a new study says. ... higher infection risk among kids with arthritis, other arthritis ... inhibitors -- were not. Researchers analyzed Medicaid ...
... can have as much effect on the teens, substance ... "Among friendship groups with ,good parents, there,s a ... aware of your whereabouts, and your friends, parents are ... you are less likely to use substances," said Michael ...
... announced today the inaugural class of its Presidential ... early career researchers with financial support to attend ... exclusive networking and mentoring opportunities with AcademyHealth leadership ... "The presidential scholarships are an opportunity for ...
... 1, 2012 Scientists at Joslin Diabetes Center have identified ... rapamycin) protein kinase, a critical regulator of cell growth which ... finding not only illuminates the physiology of aging but could ... conditions, such as cancer, type 2 diabetes, and neurodegeneration. ...
Cached Medicine News:Health News:University of Houston Graduate College of Social Work announces partnership with MD Anderson 2Health News:Researchers determine vitamin D blood level for reducing major medical risks in older adults 2Health News:Arthritis in Children Linked to Infections 2Health News:It takes a village to keep teens substance free 2Health News:First recipients of AcademyHealth's Presidential Scholarship announced 2Health News:Joslin scientists identify important mechanism that affects the aging process 2Health News:Joslin scientists identify important mechanism that affects the aging process 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: